James R. Berenson, MD

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

James R. Berenson, MD, discusses a phase I study presented at the 2013 ASH meeting that analyzed the use weekly carfilzomib for patients with R/R multiple myeloma.

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.